Udvalget fandt, at fordelene ved MIRCERA opvejer risiciene til behandling af blodmangel ved langvarig nyresygdom.
It decided that MIRCERA’ s benefits are greater than its risks for the treatment of anaemia associated with chronic kidney disease.